CNS: NEUROLEPTIC MALIGNANT SYNDROME, extrapyramidal reactions, sedation, tardive dyskinesia.
EENT: blurred vision, dry eyes, lens opacities.
CV: hypotension, tachycardia.
GI: constipation, dry mouth, anorexia, ileus, weight gain.
GU: discoloration of urine, urinary retention.
Derm: photosensitivity, pigment changes, rashes.
Endo: galactorrhea, amenorrhea.
Hemat: AGRANULOCYTOSIS, leukopenia.
Metab: hyperthermia.
Misc: allergic reactions.
Therapeutic Classification: antiemetics, antipsychotics (conventional)
Pharmacologic Classification: phenothiazines
Absorption: Absorption from tablet is poor (approximately 20%) and variable; may be better with oral liquid formulations.
Distribution: Widely distributed, high concentrations in the CNS; crosses the placenta and enters breast milk.
Protein Binding: 
90%.
Metabolism/Excretion: Mostly metabolized by the liver (CYP2D6 isoenzyme);the CYP2D6 enzyme system exhibits genetic polymorphism; 7% of population may be poor metabolizers (PMs) and may have significantly ↑ perphenazine concentrations and an ↑ risk of adverse effects.
Half-life: 8.4–12.3 hr.
(antipsychotic effect†)
†Optimal antipsychotic response may not occur for several wk.
